Key Market Indicators
Sales of diabetes medicine in Canada are expected to reach nearly $3 billion by 2026, up from $2.5 billion in 2021. This marks an average year-on-year growth rate of 2.7%. This follows a 11.5% year-on-year rise since 2017. Canada was the second-largest market in 2021, with Germany leading the way with sales of $2.5 billion. Canada was followed by Spain and Italy in third and fourth place respectively. Imports of insulin to Canada are projected to reach nearly $457 million by 2026, up from $407 million in 2021. This is an average year-on-year growth rate of 2.4%. This follows a 3.1% year-on-year increase since 1994. Exports of insulin from Canada are estimated to reach $1.2 billion by 2026, down from $2.6 billion in 2021. This represents an average year-on-year decrease of 10.5%. This follows a 43.1% year-on-year decline since 1994. In 2021, Canada was the 29th largest exporter of insulin, with Australia leading the way with exports of $2.6 billion. France, Italy and China came in second, third and fourth place respectively.
